Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Ahn on the Role of Checkpoint Inhibitors in NTRK Fusion+ MSI-H CRC

November 10th 2020

Daniel H. Ahn, DO, discusses the role of checkpoint inhibitor therapy in patients with microsatellite instability–high colorectal cancer who harbor an NTRK fusion.

Dr. Cavnar on the Management of Liver Metastases in CRC

November 5th 2020

Michael J. Cavnar, MD, discusses the management of patients with liver metastases in colorectal cancer.

Dr. Bekaii-Saab on the Future of Telemedicine in CRC

November 4th 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses the future of telemedicine in colorectal cancer.

USPSTF Gives Grade B Recommendation for Lower CRC Screening Age, Lists Cologuard as a Suggested Screening Method

November 3rd 2020

The United States Preventive Services Task Force now recommends that colorectal cancer screening begin 5 years earlier, at age 45 versus age 50, according to new draft guidelines.

Dr. Azad on Selecting Between Regorafenib and TAS-102 in CRC

October 30th 2020

Nilofer Saba Azad, MD, discusses selecting between regorafenib and TAS-102 in colorectal cancer.

Dr. Ahn on the Identification of NTRK Alterations in CRC

October 30th 2020

Daniel H. Ahn, DO, discusses the identification of NTRK alterations in colorectal cancer.

Dr. Azad on Third-Line Treatment Options in CRC

October 29th 2020

Nilofer Saba Azad, MD, discusses third-line treatment options for patients with colorectal cancer.

Dr. Bahary on the Prognosis of BRAF-Mutant Colorectal Cancer

October 28th 2020

Nathan Bahary, MD, PhD, discusses the prognosis of BRAF-mutant colorectal cancer.

Dr. Kasi on the Role of MRD Testing in CRC

October 28th 2020

Pashtoon M. Kasi, MD, MS, discusses the role of minimal residual disease testing in colorectal cancer.

Dr. Bahary on Treatment Strategies for Right- Versus Left-Sided Tumors in CRC

October 27th 2020

Nathan Bahary, MD, PhD, discusses treatment strategies for right- versus left-sided tumors in colorectal cancer.

Dr. Ahn on the Significance of the KEYNOTE-177 Trial in mCRC

October 27th 2020

Daniel H. Ahn, DO, discusses the significance of the phase 3 KEYNOTE-177 trial in patients with microsatellite instability–high metastatic colorectal cancer.

Adagrasib Shows Early Activity in KRAS G12C+ NSCLC, CRC, and Other Solid Tumors

October 26th 2020

Adagrasib, a potent and selective inhibitor of KRAS G12C, showcased encouraging clinical activity with an acceptable safety profile in patients with KRAS G12C–positive non–small cell lung cancer, colorectal cancer, and other solid tumors.

Patritumab Deruxtecan Poised for Phase 2 Exploration in HER3+ Advanced CRC

October 26th 2020

The novel HER3-targeted antibody-drug conjugate patritumab deruxtecan is currently being investigated in a phase 2 trial as a potential treatment for patients with advanced or metastatic colorectal cancer who are resistant, refractory, or intolerant to at least 2 previous lines of systemic therapy.

New Predictive Test Gains Momentum With 2 Positive Studies in Localized Colon Cancer

October 26th 2020

Immunoscore®, a host immune response classification tool, has demonstrated the ability to significantly affect treatment decision-making for patients with stage II colon cancer, particularly among those with high-risk disease.

AI-Powered Clinical Trial Tool Connects Young, Underserved Patients With CRC to Treatments and Research

October 24th 2020

The artificial intelligence–powered platform Clinical Trial Finder, which stemmed from a collaboration between the Colorectal Cancer Alliance and the digital health company TrialJectory, could prove beneficial for younger patients with colorectal cancer and for those who are being treated at community cancer centers.

Dr. Ahn on the Evolution of Targetable Alterations in CRC

October 23rd 2020

Daniel H. Ahn, DO, discusses the evolution of targetable alterations in colorectal cancer.

Dr. Grothey on Combination Therapies with Regorafenib and TAS-102 in CRC

October 22nd 2020

Axel Grothey, MD, discusses combination therapies with regorafenib and trifluridine/tipiracil in colorectal cancer.

Dr. Halfdanarson on the Evolving Role of Immunotherapy in CRC

October 21st 2020

Thorvardur Halfdanarson, MD, discusses the evolving role of immunotherapy in colorectal cancer.

Dr. Azad on Future Research Efforts in CRC

October 21st 2020

Nilofer Saba Azad, MD, discusses future research efforts in colorectal cancer.

Dr. Lwin on the Design of the LEAP-005 Trial in Pretreated Advanced Solid Tumors

October 20th 2020

Zarnie Lwin, MBBS, FRACP, discusses the design of the phase 2 LEAP-005 trial in previously treated patients with advanced solid tumors.